|[February 05, 2013]
BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013
RESEARCH TRIANGLE PARK, N.C. --(Business Wire)--
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth
quarter and full year 2012 financial results will be released on
Tuesday, February 19, 2013. BioCryst will host a conference call and
webcast at 11:00 a.m. Eastern Time to discuss the financial results and
to provide an update on the Company's programs. The call will be led by Jon
P. Stonehouse, President and Chief Executive Officer, Thomas
R. Staab, II, Senior Vice President and Chief Financial Officer and Dr.
William P. Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentatin may be
accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst currently has two late-stage
development programs: peramivir,
a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst has several early-stage programs: BCX4161
and a next generation oral inhibitor of plasma kallikrein for hereditary
angioedema and BCX4430,
a broad spectrum antiviral for hemorrhagic fevers. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC (News - Alert)
and located at http://investor.shareholder.com/biocryst/sec.cfm.
[ Back To Technology News's Homepage ]